Non-small cell lung cancer cells with deficiencies in homologous recombination genes are sensitive to PARP inhibitors.
Wenchao Ji, Xiang Weng, Danhua Xu...
https://pubmed.ncbi.nlm.nih.gov/31753490/Actively Recruiting
Led by Hellenic Cooperative Oncology Group · Updated on 2026-10-28
300
Participants Needed
20
Research Sites
N/A
Total Duration
Researchers are conducting a non-interventional translational research study to examine the genetic and transcriptomic features of patients with non-small cell lung cancer NSCLC. The study focuses on analyzing tumor and blood samples to uncover genomic changes, mutational patterns, and gene expression profiles linked to patient outcomes and responses to immunotherapy. Approximately 300 patients with confirmed NSCLC, including both early-stage and metastatic cases, will participate. Participants will provide formalin-fixed paraffin-embedded FFPE tumor tissue and blood samples. Some may also provide fresh frozen tumor samples. The study includes whole-exome sequencing and RNA sequencing to identify clinically relevant genetic alterations, tumor mutational burden, and immune-related gene signatures. A smaller subgroup of about 20 patients with unresectable stage III NSCLC will be followed in a pilot sub-study to analyze circulating tumor DNA ctDNA over time during and after chemoradiation and durvalumab maintenance therapy. Throughout the study, researchers will collect tumor tissue, blood, and plasma samples at various timepoints. They will analyze these samples for molecular markers and track changes in ctDNA in the sub-study group. The main outcomes include the prevalence of genomic alterations, tumor mutational burden, and immune subtypes at baseline. The study aims to enhance understanding of NSCLC biology and support the discovery of biomarkers for prognosis and immunotherapy response. The study is expected to continue until the end of 2026.
CONDITIONS
Analysis of Whole Exome and Transcriptome Sequencing to Identify Prognostic Biomarkers in Patients With Non-Small Cell Lung Cancer (NSCLC)
E
Elefteria Tsolaki
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Hellenic Cooperative Oncology Group
Lead Sponsor
GlaxoSmithKline
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 5 years or until study completion
Participants provide tumor tissue and blood samples for genetic and transcriptomic testing. A subgroup will provide additional blood samples over time for circulating tumor DNA analysis during treatment and follow-up.
Initial sample collection and periodic blood draws for sub-study participants
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Wenchao Ji, Xiang Weng, Danhua Xu...
https://pubmed.ncbi.nlm.nih.gov/31753490/J Nicholas Bodor, Yanis Boumber, Hossein Borghaei
https://pubmed.ncbi.nlm.nih.gov/31691957/Jason Beattie, Lonny Yarmus, Momen Wahidi...
https://pubmed.ncbi.nlm.nih.gov/29756991/Siddhartha Devarakonda, Daniel Morgensztern, Ramaswamy Govindan
https://pubmed.ncbi.nlm.nih.gov/26149886/Heng Li
https://pubmed.ncbi.nlm.nih.gov/22569178/Cancer Genome Atlas Research Network
https://pubmed.ncbi.nlm.nih.gov/22960745/Cancer Genome Atlas Research Network
https://pubmed.ncbi.nlm.nih.gov/25079552/Alex Friedlaender, Joshua Bauml, Giuseppe Luigi Banna...
https://pubmed.ncbi.nlm.nih.gov/31807145/Rosario Garcia-Campelo, Oscar Arrieta, Bartomeu Massuti...
https://pubmed.ncbi.nlm.nih.gov/33070053/Arielle L Heeke, Michael J Pishvaian, Filipa Lynce...
https://pubmed.ncbi.nlm.nih.gov/30234181/Hellenic Cooperative Oncology Group
Lead Sponsor
GlaxoSmithKline
Collaborating Sponsor